REUTERS
January 14, 2023 at 07:40 JST
A sample vial of mRNA-based COVID-19 vaccine developed by Daiichi Sankyo Co. (Provided by Daiichi Sankyo Co.)
Daiichi Sankyo Co. said on Friday it submitted its mRNA-based COVID-19 vaccine for regulatory approval in Japan.
Approval would give Japan a home-grown mRNA vaccine of the type that have made up the bulk of its COVID inoculations so far. The vaccine known as DS-5670 is being proposed as a booster shot, Daiichi Sankyo said in a statement.
In a trial of about 5,000 Japanese adults, those who received the vaccine developed levels of COVID antibodies that were as good as or better than those of people who got other mRNA shots, the company said in November.
Daiichi Sankyo said it plans to move forward to develop DS-5670 to target the Omicron strain of the coronavirus.
Japan has relied mainly on imports of shots developed by U.S. drugmakers Pfizer Inc. and Moderna Inc.
Daiichi Sankyo in talks with AstraZeneca on virus vaccine supply in Japan
June 26, 2020
Japan’s Shionogi starts Phase II/III clinical trial for new COVID-19 vaccine
October 21, 2021
Before COVID-19, Japan ‘lost’ 2 decades in vaccine research
April 28, 2021
Japan’s AnGes speeds toward 2021 rollout in ‘vaccine war’
June 10, 2020
Japan’s ruling party to urge sharing AstraZeneca’s COVID-19 shot to Taiwan
May 28, 2021
Japan to consider sharing COVID-19 vaccines amid calls to help Taiwan
May 29, 2021
Stories about memories of cherry blossoms solicited from readers
Cooking experts, chefs and others involved in the field of food introduce their special recipes intertwined with their paths in life.
A series based on diplomatic documents declassified by Japan’s Foreign Ministry
A series on the death of a Japanese woman that sparked a debate about criminal justice policy in the United States
A series about Japanese-Americans and their memories of World War II
Here is a collection of first-hand accounts by “hibakusha” atomic bomb survivors.
